GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » YIFAN PHARMACEUTICAL CO LTD (SZSE:002019) » Definitions » COGS-to-Revenue

YIFAN PHARMACEUTICAL CO (SZSE:002019) COGS-to-Revenue : 0.53 (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is YIFAN PHARMACEUTICAL CO COGS-to-Revenue?

YIFAN PHARMACEUTICAL CO's Cost of Goods Sold for the three months ended in Mar. 2024 was ¥698 Mil. Its Revenue for the three months ended in Mar. 2024 was ¥1,326 Mil.

YIFAN PHARMACEUTICAL CO's COGS to Revenue for the three months ended in Mar. 2024 was 0.53.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. YIFAN PHARMACEUTICAL CO's Gross Margin % for the three months ended in Mar. 2024 was 47.37%.

YIFAN PHARMACEUTICAL CO COGS-to-Revenue Historical Data

The historical data trend for YIFAN PHARMACEUTICAL CO's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

YIFAN PHARMACEUTICAL CO COGS-to-Revenue Chart

YIFAN PHARMACEUTICAL CO Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.54 0.54 0.59 0.51 0.52

YIFAN PHARMACEUTICAL CO Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 0.48 0.49 0.59 0.53

YIFAN PHARMACEUTICAL CO COGS-to-Revenue Calculation

YIFAN PHARMACEUTICAL CO's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=2121.932 / 4068.107
=0.52

YIFAN PHARMACEUTICAL CO's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=697.907 / 1325.969
=0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

YIFAN PHARMACEUTICAL CO  (SZSE:002019) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

YIFAN PHARMACEUTICAL CO's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 697.907 / 1325.969
=47.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

YIFAN PHARMACEUTICAL CO COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of YIFAN PHARMACEUTICAL CO's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

YIFAN PHARMACEUTICAL CO (SZSE:002019) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » YIFAN PHARMACEUTICAL CO LTD (SZSE:002019) » Definitions » COGS-to-Revenue
Comparable Companies
SZSE:300357 SHSE:600771 SZSE:301096 SZSE:300109 SHSE:600713 SZSE:000411 SZSE:301507 SHSE:600666 SHSE:600613 SZSE:002198 LLY JNJ MRK ABBV LSE:AZN XSWX:NOVN XSWX:ROG AMGN PFE XPAR:SAN
Traded in Other Exchanges
N/A
Address
No. 50 Qinshan, Jincheng, Lin'an Economic Development Zone, Hangzhou, Zhejiang, CHN, 311300
Website
https://en.yifanyy.com
YIFAN PHARMACEUTICAL CO LTD is a China-based company engaged in pharmaceutical innovation and manufacturing. The company focuses its activities on key areas like macromolecular biologics, high-value pharmaceuticals, and differentiated traditional Chinese medicines. The products of the company are F-627 for Neutropenia and Parkinson's disease, F-652 for acute alcoholic hepatitis, GvHD and acute pancreatitis and F-899 for growth deficiency. The company's products are sold in China and internationally.
Executives
Ye Yi Qun Director
Zhang Da Wei Executives
Geng Yu Hong Executives
Feng De Qi Directors, Directors, and Executives
Zhou Ben Yu Director
Lin Xing Directors, executives
Yu Hai Xia Executives
Cheng Xian Feng Directors, executives
Xu Guo Han Supervisors
Cao Shi Mei Director
Lin Guan Yu Director
Zhang Lian Chun Executives
Guo Xin Fu Director
Zheng Shi Ming Supervisors
Yin Hang Hua Executives

YIFAN PHARMACEUTICAL CO (SZSE:002019) Headlines

No Headlines